TGF-βRI Kinase Activity Mediates Emdogain-stimulated in Vitro Osteoclastogenesis

Overview

Journal Clin Oral Investig

Specialty Dentistry

Date 2013 Nov 14

PMID 24221580

Citations 9

Authors

Reinhard Gruber

Gilles Roos

Jordi Caballe-Serrano

Rick Miron

Dieter D Bosshardt

Anton Sculean

Affiliations

Soon will be listed here.

Abstract

Objectives: Emdogain, containing an extract of fetal porcine enamel matrix proteins, is a potent stimulator of in vitro osteoclastogenesis. The underlying molecular mechanisms are, however, unclear.

Material And Methods: Here, we have addressed the role of transforming growth factor-beta receptor type 1 (TGF-βRI) kinase activity on osteoclastogenesis in murine bone marrow cultures.

Results: Inhibition of TGF-βRI kinase activity with SB431542 abolished the effect of Emdogain on osteoclastogenesis induced by receptor activator of nuclear factor kappa-B ligand or tumor necrosis factor-alpha. SB431542 also suppressed the Emdogain-mediated increase of OSCAR, a co-stimulatory protein, and dendritic cell-specific transmembrane protein and Atp6v0d2, the latter two being involved in cell fusion. Similar to transforming growth factor-beta1 (TGF-β), Emdogain could not compensate for the inhibition of IL-4 and IFNγ on osteoclast formation. When using the murine macrophage cell line RAW246.7, SB431542 and the smad-3 inhibitor SIS3 blocked Emdogain-stimulated expression of the transcription factor NFATc1.

Conclusions: Taken together, the data suggest that TGF-βRI kinase activity is necessary to mediate in vitro effects of Emdogain on osteoclastogenesis.

Clinical Relevance: Based on these in vitro data, we can speculate that at least part of the clinical effects of Emdogain on osteoclastogenesis is mediated via TGF-β signaling.

Citing Articles

RNAseq of peripheral blood mononucleated cells exposed to platelet-rich fibrin and enamel matrix derivatives.

Panahipour L, Kargarpour Z, Mildner M, Kuhtreiber H, Gruber R Sci Rep. 2025; 15(1):3661.

PMID: 39881164 PMC: 11779933. DOI: 10.1038/s41598-025-86791-5.

Enamel Matrix Derivative Suppresses Chemokine Expression in Oral Epithelial Cells.

Panahipour L, Botta S, Abbasabadi A, Afradi Z, Gruber R Int J Mol Sci. 2023; 24(18).

PMID: 37762294 PMC: 10530986. DOI: 10.3390/ijms241813991.

TGF-β Signalling Mediates the Anti-Inflammatory Activity of Enamel Matrix Derivative In Vitro.

Panahipour L, Sordi M, Kargarpour Z, Gruber R Int J Mol Sci. 2022; 23(17).

PMID: 36077174 PMC: 9456059. DOI: 10.3390/ijms23179778.

comparative study of the effects of using the enamel matrix derivative and/or photobiomodulation on the repair of bone defects.

Garcia V, Calil V, Cardoso J, Hinz M, da Rocha T, Ervolino E J Clin Exp Dent. 2022; 14(2):e114-e122.

PMID: 35173893 PMC: 8842292. DOI: 10.4317/jced.59179.

The role of menin in bone pathology.

Gorbacheva A, Eremkina A, Goliusova D, Krupinova J, Mokrysheva N Endocr Connect. 2022; 11(3).

PMID: 35148273 PMC: 8942318. DOI: 10.1530/EC-21-0494.

References

Kon T, Cho T, Aizawa T, Yamazaki M, Nooh N, Graves D . Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing. J Bone Miner Res. 2001; 16(6):1004-14. DOI: 10.1359/jbmr.2001.16.6.1004. View

Fridstrom M, Schollin J, Crossner C . Evaluating Emdogain and healing of replanted teeth using an intra-individual experimental-control study design. Dent Traumatol. 2008; 24(3):299-304. DOI: 10.1111/j.1600-9657.2008.00559.x. View

FOX S, Fuller K, Bayley K, Lean J, Chambers T . TGF-beta 1 and IFN-gamma direct macrophage activation by TNF-alpha to osteoclastic or cytocidal phenotype. J Immunol. 2000; 165(9):4957-63. DOI: 10.4049/jimmunol.165.9.4957. View

Itoh N, Kasai H, Ariyoshi W, Harada E, Yokota M, Nishihara T . Mechanisms involved in the enhancement of osteoclast formation by enamel matrix derivative. J Periodontal Res. 2006; 41(4):273-9. DOI: 10.1111/j.1600-0765.2005.00868.x. View

Lou Z, Yang Y, Ren T, Tang S, Peng X, Lu Q . Smad3 is the key to transforming growth factor-β1-induced osteoclast differentiation in giant cell tumor of bone. Med Oncol. 2013; 30(3):606. DOI: 10.1007/s12032-013-0606-8. View

Thirunavukkarasu K, Miles R, Halladay D, Yang X, Galvin R, Chandrasekhar S . Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. J Biol Chem. 2001; 276(39):36241-50. DOI: 10.1074/jbc.M104319200. View

Koga T, Inui M, Inoue K, Kim S, Suematsu A, Kobayashi E . Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature. 2004; 428(6984):758-63. DOI: 10.1038/nature02444. View

Hamamoto Y, Kawasaki N, Jarnbring F, Hammarstrom L . Effects and distribution of the enamel matrix derivative Emdogain in the periodontal tissues of rat molars transplanted to the abdominal wall. Dent Traumatol. 2002; 18(1):12-23. DOI: 10.1034/j.1600-9657.2002.180102.x. View

Gruber R, Bosshardt D, Miron R, Gemperli A, Buser D, Sculean A . Enamel matrix derivative inhibits adipocyte differentiation of 3T3-L1 cells via activation of TGF-βRI kinase activity. PLoS One. 2013; 8(8):e71046. PMC: 3741362. DOI: 10.1371/journal.pone.0071046. View

10.

Kukita T, Wada N, Kukita A, Kakimoto T, Sandra F, Toh K . RANKL-induced DC-STAMP is essential for osteoclastogenesis. J Exp Med. 2004; 200(7):941-6. PMC: 2213286. DOI: 10.1084/jem.20040518. View

11.

Heng N, NGuessan P, Kleber B, Bernimoulin J, Pischon N . Enamel matrix derivative induces connective tissue growth factor expression in human osteoblastic cells. J Periodontol. 2007; 78(12):2369-79. DOI: 10.1902/jop.2007.070130. View

12.

Otsuka T, Kasai H, Yamaguchi K, Nishihara T . Enamel matrix derivative promotes osteoclast cell formation by RANKL production in mouse marrow cultures. J Dent. 2005; 33(9):749-55. DOI: 10.1016/j.jdent.2005.02.006. View

13.

Edwards J, Nyman J, Lwin S, Moore M, Esparza J, OQuinn E . Inhibition of TGF-β signaling by 1D11 antibody treatment increases bone mass and quality in vivo. J Bone Miner Res. 2010; 25(11):2419-26. DOI: 10.1002/jbmr.139. View

14.

Filippi A, Pohl Y, von Arx T . Treatment of replacement resorption by intentional replantation, resection of the ankylosed sites, and Emdogain--results of a 6-year survey. Dent Traumatol. 2006; 22(6):307-11. DOI: 10.1111/j.1600-9657.2005.00363.x. View

15.

Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie M, Martin T . Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 1999; 20(3):345-57. DOI: 10.1210/edrv.20.3.0367. View

16.

Boyle W, Simonet W, Lacey D . Osteoclast differentiation and activation. Nature. 2003; 423(6937):337-42. DOI: 10.1038/nature01658. View

17.

Quinn J, Itoh K, Udagawa N, Hausler K, Yasuda H, Shima N . Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. J Bone Miner Res. 2001; 16(10):1787-94. DOI: 10.1359/jbmr.2001.16.10.1787. View

18.

Mohammad K, Chen C, Balooch G, Stebbins E, McKenna C, Davis H . Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS One. 2009; 4(4):e5275. PMC: 2666804. DOI: 10.1371/journal.pone.0005275. View

19.

Yasui T, Kadono Y, Nakamura M, Oshima Y, Matsumoto T, Masuda H . Regulation of RANKL-induced osteoclastogenesis by TGF-β through molecular interaction between Smad3 and Traf6. J Bone Miner Res. 2011; 26(7):1447-56. DOI: 10.1002/jbmr.357. View

20.

Kawase T, Okuda K, Momose M, Kato Y, Yoshie H, Burns D . Enamel matrix derivative (EMDOGAIN) rapidly stimulates phosphorylation of the MAP kinase family and nuclear accumulation of smad2 in both oral epithelial and fibroblastic human cells. J Periodontal Res. 2002; 36(6):367-76. DOI: 10.1034/j.1600-0765.2001.360604.x. View